Alto Neuroscience ANRO Change in fair value attributable to instrument specific credit risk
Change in fair value attributable to instrument specific credit risk at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:OciMarketRiskBenefitInstrumentSpecificCreditRiskGainLossAfterAdjustmentsAndTaxParent.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's change in fair value attributable to instrument specific credit risk.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's change in fair value attributable to instrument specific credit risk?
- Alto Neuroscience (ANRO) reported change in fair value attributable to instrument specific credit risk of $7K in Q1 2026.
- How has Alto Neuroscience's change in fair value attributable to instrument specific credit risk changed year-over-year?
- Alto Neuroscience's change in fair value attributable to instrument specific credit risk decreased by 94.8% year-over-year, from $134K to $7K.
- What does change in fair value attributable to instrument specific credit risk mean?
- This metric captures the portion of the change in fair value of financial liabilities that is attributable to changes in the company's own credit risk. It is recognized within other comprehensive income to prevent volatility in net income caused by fluctuations in the entity's creditworthiness. Tracking this helps investors understand how market perceptions of the company's financial stability influence the valuation of its debt-like instruments.